iTeos Belgium SA
- Country
- π§πͺBelgium
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
- Conditions
- Selected Advanced Solid Tumors
- Interventions
- Drug: EOS006215Drug: Anticancer agent
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 3
- Registration Number
- NCT06877533
- Locations
- πΊπΈ
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
πΊπΈFlorida Cancer Specialists (FSC SAC DDU) Sarasota, Sarasota, Florida, United States
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Locally Advanced NSCLC - Non-Small Cell Lung CancerMetastatic NSCLC - Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 36
- Registration Number
- NCT05403385
- Locations
- πΊπΈ
Highlands Oncology Group, Fayetteville, Arkansas, United States
πΊπΈH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
π§πͺAlgemeen Ziekenhuis Sint-Lucas, Gent, Belgium
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 16
- Registration Number
- NCT05289492
- Locations
- πΊπΈ
Banner MD Anderson, Gilbert, Arizona, United States
πΊπΈEastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
πΊπΈHackensack University Medical Center, Hackensack, New Jersey, United States
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Conditions
- Head and Neck CancerAdvanced CancerLung CancerMelanoma
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 153
- Registration Number
- NCT05060432
- Locations
- πΊπΈ
University of California San Diego, San Diego, California, United States
πΊπΈHackensack University Medical Center, Bergen, New Jersey, United States
π§πͺGZA Ziekenhuizen campus Sint-Augustinus, Antwerpen, Antwerp, Belgium
First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 40
- Registration Number
- NCT04335253
- Locations
- π§πͺ
GZA Ziekenhuizen campus Sint-Augustinus, Antwerp, Belgium
π§πͺInstitut Jules Bordet, Brussels, Belgium
π§πͺCliniques universitaires St Luc-UCL, Brussels, Belgium